| 引用本文：王煜昊, 徐伟, 路娜娜, 张圣和, 尚波波, 刘朝一, 黄晓青.“4+7”集中带量采购实施效果分析——基于9试点地区药品销售数据[J].中国卫生政策研究,2021,14(2):36-43 |
|
| “4+7”集中带量采购实施效果分析——基于9试点地区药品销售数据 |
| 投稿时间：2020-09-24 修订日期：2021-02-10 PDF全文浏览 HTML全文浏览 |
| 王煜昊, 徐伟, 路娜娜, 张圣和, 尚波波, 刘朝一, 黄晓青 |
| 中国药科大学国际医药商学院 江苏南京 211198 |
| 摘要:目的：剖析“4+7”集中带量采购政策的实施效果。方法：基于药品销售数据及中标企业年报数据，对纳入“4+7”集中带量采购范围的药品在政策实施前后的销售额，原研厂家、中标企业及其他企业的销售额及市场占有率进行对比分析，同时对部分中标企业营收情况的变化进行比较。结果：“4+7”集中带量采购实施后，绝大部分纳入集采品种销售额较往年有显著下降，其中，原研企业、其他企业均有较大幅度下滑，中标企业虽涨跌参半，但已形成对仿制药市场的垄断。此外，“4+7”集中带量采购能够在一定程度上起到促进药品生产企业积极转型，加大研发投入的作用。结论：集中带量采购颇有成效，坚持之余要慎防垄断；要完善医保支付标准的建设，健全原研药、仿制药、过专利期原研药的联动机制；集中带量采购的品种选择应由“点”至“面”。 |
| 关键词:集中带量采购 药品价格 实施效果 |
| 基金项目:中国药科大学“双一流”学科创新团队项目（CPU2018GY43） |
|
| Analysis of the effect of “4+7” centralized procurement policy implementation: Based on the drug sales data of 9 pilot regions |
| WANG Yu-hao, XU Wei, LU Na-na, ZHANG Sheng-he, SHANG Bo-bo, LIU Chao-yi, HUANG Xiao-qing |
| School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing Jiangsu 211198, China |
| Abstract:Objective: To analyze the implementation effect of the “4+7” centralized procurement policy. Methods: Based on the drug sales data and the annual report data of the bid winning enterprises, the sales volume of the drugs included in the “4+7” centralized procurement scope before and after the implementation of the policy, the sales volume and market share of the original research manufacturers, bid winning enterprises and other enterprises were compared and analyzed. The changes in the revenues of some bid-winning companies were also compared. Results: After the implementation of the “4+7” centralized procurement policy, the sales volume of most of the varieties included in centralized procurement have significantly decreased compared with the cases in previous years. Among them, the original research companies and other companies have experienced significant declines. Although the bid-winning companies have experienced mixed gains and falls, they had formed a monopoly on the generic drug market. In addition, the “4+7” centralized procurement policy can play a role in promoting the active transformation of drug manufacturers and increasing R&D investment to a certain extent. Conclusions: The policy of centralized procurement with volume/quantity is quite effective, but careful attention should be paid to prevent monopoly. At the same time, the construction of medical insurance payment standards and the linkage mechanism of original research drugs, generic drugs, and original research drugs beyond the patent period should be improved; and the selection of various drugs in the policy of centralized procurement with quantity should be changed from “point” to “surface”. |
| Key words:Centralized procurement Drug price Implementation effect |
| 摘要点击次数: 2850 全文下载次数: 1018 |
|
|
|
|
|
